[1] McGregor MM, Nelson AB.  Circuit mechanisms of Parkinson's disease[J]. Neuron, 2019, 101(6): 1042-1056.   doi: 10.1016/j.neuron.2019.03.004
[2] 李玲, 吴平, 邬剑军, 等.  多巴胺转运体PET显像对帕金森病和进行性核上性麻痹的鉴别诊断价值研究[J]. 中国临床神经科学, 2018, 26(3): 262-268.   doi: 10.3969/j.issn.1008-0678.2018.03.004
Li L, Wu P, Wu JJ, et al.  Dopamine transporter PET imaging in patients with progressive supranuclear palsy and Parkinson's disease[J]. Chin J Clin Neurosci, 2018, 26(3): 262-268.   doi: 10.3969/j.issn.1008-0678.2018.03.004
[3] 辛玫, 张晨鹏, 王成, 等.  震颤与非震颤帕金森病患者11C-CFT和18F-FDG PET/CT显像的代谢特点[J]. 中华核医学与分子影像杂志, 2019, 38(6): 344-348.   doi: 10.3760/cma.j.issn.2095-2848.2019.06.005
Xin M, Zhang CP, Wang C, et al.  Metabolic patterns of 11C-CFT and 18F-FDG PET/CT imaging in tremor and non-tremor Parkinson's[J]. Chin J Nucl Med Mol Imaging, 2019, 38(6): 344-348.   doi: 10.3760/cma.j.issn.2095-2848.2019.06.005
[4] Calne DB, Snow BJ, Lee C.  Criteria for diagnosing Parkinson's disease[J]. Ann Neurol, 1992, 32(S1): S125-127.   doi: 10.1002/ana.410320721
[5] 冼文彪, 史新冲, 张祥松, 等.  [11C]CFT脑多巴胺转运体PET显像对帕金森病诊断和严重程度评估的应用[J]. 中国神经精神疾病杂志, 2014, 40(8): 474-478.   doi: 10.3936/j.issn.1002-0152.2014.08.006
Xian WB, Shi XC, Zhang XS, et al.  Applicationof [11C]CFT dopamine transporter PET imaging in the diagnosis and severity assessment of Parkinson disease[J]. Chin J Nerv Ment Dis, 2014, 40(8): 474-478.   doi: 10.3936/j.issn.1002-0152.2014.08.006
[6] Hoehn MM, Yahr MD.  Parkinsonism: onset, progression and mortality[J]. Neurology, 1967, 17(5): 427-442.   doi: 10.1212/wnl.17.5.427
[7] 宁静, 杨晖, 李灿, 等.  11C-CFT PET/CT显像与帕金森病综合评定量表评分相关性分析[J]. 中华保健医学杂志, 2020, 22(1): 49-52.   doi: 10.3969/j.issn.1674-3245.2020.01.014
Ning J, Yang H, Li C, et al.  Correlation analysis between PET/CT imaging of 11C-CFT and UPDRS in Parkinson's disease[J]. Chin J Health Care Med, 2020, 22(1): 49-52.   doi: 10.3969/j.issn.1674-3245.2020.01.014
[8] 左传涛, 王坚, 黄喆慜, 等.  统计参数图和ROI联合应用在多巴胺转运蛋白PET显像分析中的价值[J]. 中华核医学杂志, 2008, 28(1): 7-10.   doi: 10.3760/cma.j.issn.2095-2848.2008.01.003
Zuo CT, Wang J, Huang ZM, et al.  The value of combining statistical parametric mapping and ROI methods in DAT imaging analysis[J]. Chin J Nucl Med Mol Imaging, 2008, 28(1): 7-10.   doi: 10.3760/cma.j.issn.2095-2848.2008.01.003
[9] 王营飞, 贺娟, 张学敏.  帕金森病的早期症状与诊断方法研究进展[J]. 医学综述, 2018, 24(12): 2441-2445.   doi: 10.3969/j.issn.1006-2084.2018.12.028
Wang YF, He J, Zhang XM.  Research advances in early symptoms and diagnostic methods of Parkinson's disease[J]. Med Recapitul, 2018, 24(12): 2441-2445.   doi: 10.3969/j.issn.1006-2084.2018.12.028
[10] Ishibashi K, Oda K, Ishiwata K, et al.  Comparison of dopamine transporter decline in a patient with Parkinson's disease and normal aging effect[J]. J Neurol Sci, 2014, 339(1/2): 207-209.   doi: 10.1016/j.jns.2014.01.015
[11] Odekerken VJJ, van Laar T, Staal MJ, et al.  Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial[J]. Lancet Neurol, 2013, 12(1): 37-44.   doi: 10.1016/S1474-4422(12)70264-8
[12] 杨晖, 李灿, 杜磊, 等.  对比年轻型与老年型帕金森病的多巴胺转运蛋白及D2受体PET显像[J]. 中国医学影像技术, 2018, 34(11): 1610-1614.   doi: 10.13929/j.1003-3289.201805160
Yang H, Li C, Du L, et al.  Comparison of dopamine transporter and D2 receptor imaging in young and late onset Parkinson disease[J]. Chin J Med Imaging Technol, 2018, 34(11): 1610-1614.   doi: 10.13929/j.1003-3289.201805160
[13] 沈杨, 张琦, 赵佳奇, 等.  阿尔兹海默病与帕金森病共性病理机制研究进展[J]. 中华中医药学刊, 2018, 36(2): 319-322.   doi: 10.13193/j.issn.1673-7717.2018.02.015
Shen Y, Zhang Q, Zhao JQ, et al.  Common pathological mechanism of Alzheimer's disease and Parkinson's disease[J]. Chin Arch Tradit Chin Med, 2018, 36(2): 319-322.   doi: 10.13193/j.issn.1673-7717.2018.02.015
[14] 袁晶, 王含, 万新华.  帕金森病相关认知功能障碍[J]. 中国现代神经疾病杂志, 2017, 17(6): 409-414.   doi: 10.3969/j.issn.1672-6731.2017.06.004
Yuan J, Wang H, Wan XH.  Cognitive impairment in Parkinson's disease[J]. Chin J Contemp Neurol Neurosurg, 2017, 17(6): 409-414.   doi: 10.3969/j.issn.1672-6731.2017.06.004
[15] Li XH, Zhang QZ, Qin YD, et al.  Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease[J]. Medicine, 2020, 99(14): e19662-.   doi: 10.1097/MD.0000000000019662
[16] 王坚, 蒋雨平, 项景德, 等.  18F-FP-β-CIT PET脑显像在早期诊断帕金森病中的意义[J]. 中华核医学杂志, 2003, 23(4): 216-218.   doi: 10.3760/cma.j.issn.2095-2848.2003.04.009
Wang J, Jiang YP, Xiang JD, et al.  The significance of 18F-FP-β-CIT dopamine transporter PET imaging in early diagnosis of Parkinson's disease[J]. Chin J Nucl Med Mol Imaging, 2003, 23(4): 216-218.   doi: 10.3760/cma.j.issn.2095-2848.2003.04.009
[17]

McNeill A, Wu RM, Tzen KY, et al. Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis[J/OL]. PLoS One, 2013, 8(7): e69190[2022-02-06]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069190. DOI: 10.1371/journal.pone.0069190.
[18] Lin W, Zuo CT, Wu JJ, et al.  Striatal asymmetry index and its correlation with the Hoehn & Yahr stage in Parkinson's disease[J]. Int J Neurosci, 2022, 132(2): 165-170.   doi: 10.1080/00207454.2020.1806265
[19] Nurmi E, Bergman J, Eskola O, et al.  Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET[J]. Synapse, 2003, 48(3): 109-115.   doi: 10.1002/syn.10192
[20] El Fakhri G, Habert MO, Maksud P, et al.  Quantitative simultaneous 99mTc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy[J]. Eur J Nucl Med Mol Imaging, 2006, 33(1): 87-92.   doi: 10.1007/s00259-005-1920-y
[21] Scherfler C, Seppi K, Donnemiller E, et al.  Voxel-wise analysis of [123I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease[J]. Brain, 2005, 128(7): 1605-1612.   doi: 10.1093/brain/awh485
[22] Rosano C, Metti AL, Rosso AL, et al.  Influence of striatal dopamine, cerebral small vessel disease, and other risk factors on age-related parkinsonian motor signs[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(4): 696-701.   doi: 10.1093/gerona/glz161
[23] Liu SY, Wu JJ, Zhao J, et al.  Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: a positron emission tomography study[J]. Parkinsonism Relat Disord, 2015, 21(12): 1448-1453.   doi: 10.1016/j.parkreldis.2015.10.017
[24] 赵振凡, 陶俊, 许志强, 等.  11C-CFT脑多巴胺转运体PET显像对帕金森病进展及严重程度的评价[J]. 西部医学, 2017, 29(6): 782-785, 790.   doi: 10.3969/j.issn.1672-3511.2017.06.009
Zhao ZF, Tao J, Xu ZQ, et al.  Application of 11C-CFT dopamine transporter PET imaging in the assessment of progression and severity of Parkinson's disease[J]. Med J West China, 2017, 29(6): 782-785, 790.   doi: 10.3969/j.issn.1672-3511.2017.06.009